Two Sigma Advisers LP Has $50.60 Million Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Two Sigma Advisers LP reduced its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 33.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,950,124 shares of the biotechnology company's stock after selling 1,504,276 shares during the quarter. Two Sigma Advisers LP owned 1.25% of ADMA Biologics worth $50,595,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Perpetual Ltd acquired a new stake in ADMA Biologics in the 4th quarter valued at about $62,300,000. Allspring Global Investments Holdings LLC raised its stake in ADMA Biologics by 1,144.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after acquiring an additional 2,613,482 shares during the period. B Group Inc. acquired a new stake in ADMA Biologics during the 4th quarter valued at $39,231,000. Raymond James Financial Inc. acquired a new stake in ADMA Biologics during the 4th quarter valued at $19,076,000. Finally, Arrowstreet Capital Limited Partnership boosted its position in ADMA Biologics by 57.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company's stock worth $47,380,000 after purchasing an additional 1,013,456 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Trading Up 2.5%

Shares of ADMA stock opened at $20.19 on Tuesday. The stock has a 50 day simple moving average of $20.52 and a 200 day simple moving average of $18.88. ADMA Biologics, Inc. has a 1 year low of $9.22 and a 1 year high of $25.67. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a market cap of $4.82 billion, a P/E ratio of 72.11 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). The firm had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company's revenue for the quarter was up 40.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.08 EPS. On average, research analysts predict that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ADMA. Raymond James raised their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th. Finally, StockNews.com downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, ADMA Biologics currently has an average rating of "Moderate Buy" and a consensus price target of $24.25.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.